Clinical Research Life Science Pharma Companies Regulation 
pharmaphorum
FEBRUARY 11, 2021
Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research.
pharmaphorum
MAY 27, 2022
wearable device carried by patients to measure certain health-related parameters, remote patient monitoring) and tele-healthcare in clinical trials (e.g. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. video consultations), health data analytics (e.g.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 31, 2021
For the innovators and early adopters of the life sciences industry, engineering a regulatory-grade ECA can be daunting. However, if history is any indication, pharma companies have been risk-averse when it comes to fully immersing itself into the expanded use of RWE in our development efforts.
pharmaphorum
JULY 8, 2022
“They can solve some immediate challenges with participation in research by conducting eCOA (electronic clinical outcome assessment) remotely or doing virtual visits. We have also seen the regulators actively support the use of these hybrid decentralised research approaches. Novel digital endpoints.
XTalks
MAY 6, 2022
In this interview, Xtalks spoke with experts from eClinical Solutions , Katrina Rice, Chief Delivery Officer, Data Services; and Diane Lacroix, Vice President, Clinical Data Management, about clinical data management for modern day digital clinical trials. Clinical Data Pipeline for Data Review and Analyses.
pharmaphorum
DECEMBER 16, 2020
Soon the ABPI and the entire industry were facing the ripple effects of COVID-19, including a significant slowdown in non-COVID clinical research, which Torbett says was challenging for the industry to deal with. “We’ve We had companies collaborating to develop laboratories. A collaborative future.
pharmaphorum
APRIL 7, 2021
With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharma companies and will aim to keep more product rights than it did in the past. In good shape. We are in a crisis.
Expert insights. Personalized for you.
101 
Let's personalize your content